How often to review taking Rosuvastatin needs to be discussed separately for each case. Those taking lipid-lowering drugs such as statins require close lipid monitoring. For those taking lipid-lowering drugs for the first time, blood lipids and liver function, renal function and creatine kinase (CK) and blood glucose should be rechecked within 4 to 6 weeks of drug administration. If the lipids can reach the target value and there is no adverse drug reaction, gradually change to review every 6 to 12 months; if the lipids do not reach the target value and there is no adverse drug reaction, monitor every 3 months. If lipids still do not reach the target value after 3 to 6 months of treatment, it is necessary to adjust the dose or type of lipid-regulating drugs, or combine the application of lipid-regulating drugs with different mechanisms of action for treatment. Whenever the type or dose of lipid-regulating drug is adjusted, it should be reviewed within 4 to 6 weeks of treatment. Rosuvastatin, i.e., Rosuvastatin calcium, is a lipid-regulating drug, generally used for primary hypercholesterolemia, mixed dyslipidemia and other diseases in which dyslipidemia cannot be adequately controlled by dietary control and other non-pharmacological treatments, as well as for the secondary preventive treatment of patients with coronary artery disease, and for lipid-lowering and stabilizing plaque therapy. Some patients taking Rosuvastatin Calcium during the muscle pain, muscle enzyme elevation and other adverse reactions, it should be noted that, allergic to the product and active liver disease, severe renal impairment of patients prohibited the use of the drug. Specific medication should follow the doctor’s instructions.